333 related articles for article (PubMed ID: 21590447)
1. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Nolè F; Crivellari D; Mattioli R; Pinotti G; Foa P; Verri E; Fougeray R; Brandely M; Goldhirsch A
Cancer Chemother Pharmacol; 2009 Sep; 64(4):673-80. PubMed ID: 19184601
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Welt A; von Minckwitz G; Oberhoff C; Borquez D; Schleucher R; Loibl S; Harstrick A; Kaufmann M; Seeber S; Vanhoefer U
Ann Oncol; 2005 Jan; 16(1):64-9. PubMed ID: 15598940
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Favier L; Isambert N; Zanetta S; Ferrant E; Mayer F; Chauffert B; Fumoleau P; Garnier J; Biville F; Coudert B
Breast; 2008 Feb; 17(1):36-41. PubMed ID: 17698359
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
[TBL] [Abstract][Full Text] [Related]
7. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Tawfik H; Rostom Y; Elghazaly H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
9. Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study.
Delva R; Pienkowski T; Tubiana N; Vanhoefer U; Longerey B; Douville I
Cancer Chemother Pharmacol; 2007 May; 59(6):703-9. PubMed ID: 17021821
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer.
Lorusso V; Crucitta E; Silvestris N; Guida M; Misino A; Latorre A; De Lena M
Clin Breast Cancer; 2003 Jun; 4(2):138-41. PubMed ID: 12864942
[TBL] [Abstract][Full Text] [Related]
11. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer.
Nolè F; Catania C; Munzone E; Rocca A; Verri E; Sanna G; Ascione G; Adamoli L; Zampino MG; Minchella I; Goldhirsch A
Clin Breast Cancer; 2006 Feb; 6(6):518-24. PubMed ID: 16595035
[TBL] [Abstract][Full Text] [Related]
13. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients.
Ghosn M; Kattan J; Farhat F; Younes F; Gasmi J
Anticancer Res; 2006; 26(3B):2451-6. PubMed ID: 16821631
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC.
Pallis AG; Chandrinos V; Pavlakou G; Xenidis N; Varthalitis I; Vardakis N; Vamvakas L; Kontopodis E; Rovithi M; Georgoulias V
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1239-45. PubMed ID: 20697712
[TBL] [Abstract][Full Text] [Related]
18. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Villanueva C; Awada A; Campone M; Machiels JP; Besse T; Magherini E; Dubin F; Semiond D; Pivot X
Eur J Cancer; 2011 May; 47(7):1037-45. PubMed ID: 21339064
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of UFT-oral vinorelbine in metastatic breast cancer.
Ferrero JM; Largillier R; Michel C; Amiot V; Milano G; Hébert C; Mari V; Courdi A; Figl A; Follana P; Barrière J; Chamorey E
Oncology; 2011; 81(2):73-8. PubMed ID: 21968516
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
